Caisse de Depot et Placement du Quebec (CDPQ)’s Legend Biotech LEGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$293K Sell
16,216
-14,562
-47% -$278K ﹤0.01% 671
2025
Q4
$669K Buy
30,778
+4,478
+17% +$128K ﹤0.01% 534
2025
Q3
$858K Buy
+26,300
New +$971K ﹤0.01% 525
2023
Q2
Sell
-175
Closed -$8.44K 520
2023
Q1
$8.44K Sell
175
-9,478
-98% -$464K ﹤0.01% 534
2022
Q4
$482K Sell
9,653
-8,200
-46% -$397K ﹤0.01% 541
2022
Q3
$728K Buy
17,853
+328
+2% +$15.4K ﹤0.01% 498
2022
Q2
$964K Buy
17,525
+9,100
+108% +$384K ﹤0.01% 497
2022
Q1
$306K Buy
8,425
+525
+7% +$20.7K ﹤0.01% 602
2021
Q4
$368K Buy
+7,900
New +$401K ﹤0.01% 547

Other funds holding LEGN

Caisse de Depot et Placement du Quebec (CDPQ)'s LEGN Position: Q1 2026 in Review

Caisse de Depot et Placement du Quebec (CDPQ) reduced its Legend Biotech (LEGN) stake by 47% in Q1 2026, selling an estimated $278K and leaving 16,216 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Caisse de Depot et Placement du Quebec (CDPQ) first reported a position in LEGN in Q4 2021 and has held it in 9 quarters since. The position peaked at $964K in Q2 2022. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Caisse de Depot et Placement du Quebec (CDPQ) held 16,216 shares of Legend Biotech worth $293K as of Q1 2026.
  • Caisse de Depot et Placement du Quebec (CDPQ) sold 14,562 Legend Biotech shares in Q1 2026, an estimated $278K.
  • Legend Biotech made up ﹤0.01% of Caisse de Depot et Placement du Quebec (CDPQ)'s portfolio in Q1 2026, its #671 holding.
  • Caisse de Depot et Placement du Quebec (CDPQ) first reported a position in Legend Biotech in Q4 2021 and has held it in 9 quarters since.
  • Caisse de Depot et Placement du Quebec (CDPQ)'s Legend Biotech position peaked at $964K in Q2 2022.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Caisse de Depot et Placement du Quebec (CDPQ)'s 13F filing for Q1 2026, filed 14 May 2026.